메뉴 건너뛰기




Volumn 26, Issue , 2015, Pages vi50-vi54

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IBRUTINIB; IDELALISIB; METHOTREXATE; OBINUTUZUMAB; OFATUMUMAB; OXALIPLATIN; PENTOSTATIN; PREDNISOLONE; PROTEIN P53; RITUXIMAB; VINCRISTINE;

EID: 84941640385     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv303     Document Type: Article
Times cited : (303)

References (32)
  • 1
    • 45149100665 scopus 로고    scopus 로고
    • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
    • Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
    • (2008) Blood , vol.111 , pp. 5446-5456
    • Hallek, M.1    Cheson, B.D.2    Catovsky, D.3
  • 2
    • 49249119141 scopus 로고    scopus 로고
    • Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia
    • Rawstron AC, Bennett FL, O'Connor SJ et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008; 359: 575-583.
    • (2008) N Engl J Med , vol.359 , pp. 575-583
    • Rawstron, A.C.1    Bennett, F.L.2    O'Connor, S.J.3
  • 3
    • 84922529491 scopus 로고    scopus 로고
    • Recurrent mutations refine prognosis in chronic lymphocytic leukemia
    • Baliakas P, Hadzidimitriou A, Sutton LA et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015; 29: 329-336.
    • (2015) Leukemia , vol.29 , pp. 329-336
    • Baliakas, P.1    Hadzidimitriou, A.2    Sutton, L.A.3
  • 4
    • 0019427092 scopus 로고
    • A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis
    • Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
    • (1981) Cancer , vol.48 , pp. 198-206
    • Binet, J.L.1    Auquier, A.2    Dighiero, G.3
  • 5
    • 0016740933 scopus 로고
    • Clinical staging of chronic lymphocytic leukemia
    • Rai KR, Sawitsky A, Cronkite EP et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
    • (1975) Blood , vol.46 , pp. 219-234
    • Rai, K.R.1    Sawitsky, A.2    Cronkite, E.P.3
  • 6
    • 70349260657 scopus 로고    scopus 로고
    • Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience
    • Abrisqueta P, Pereira A, Rozman C et al. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. Blood 2009; 114: 2044-2050.
    • (2009) Blood , vol.114 , pp. 2044-2050
    • Abrisqueta, P.1    Pereira, A.2    Rozman, C.3
  • 7
    • 84903971364 scopus 로고    scopus 로고
    • Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
    • Pflug N, Bahlo J, Shanafelt TD et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 2014; 124: 49-62.
    • (2014) Blood , vol.124 , pp. 49-62
    • Pflug, N.1    Bahlo, J.2    Shanafelt, T.D.3
  • 8
    • 0034727833 scopus 로고    scopus 로고
    • Genomic aberrations and survival in chronic lymphocytic leukemia
    • Döhner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
    • (2000) N Engl J Med , vol.343 , pp. 1910-1916
    • Döhner, H.1    Stilgenbauer, S.2    Benner, A.3
  • 9
    • 77957664665 scopus 로고    scopus 로고
    • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomised, open-label, phase III trial
    • Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomised, open-label, phase III trial. Lancet 2010; 376: 1164-1174.
    • (2010) Lancet , vol.376 , pp. 1164-1174
    • Hallek, M.1    Fischer, K.2    Fingerle-Rowson, G.3
  • 10
    • 84855370035 scopus 로고    scopus 로고
    • SF3B1 and other novel cancer genes in chronic lymphocytic leukemia
    • Wang L, Lawrence MS, Wan Y et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365: 2497-2506.
    • (2011) N Engl J Med , vol.365 , pp. 2497-2506
    • Wang, L.1    Lawrence, M.S.2    Wan, Y.3
  • 11
    • 84901408966 scopus 로고    scopus 로고
    • Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
    • Stilgenbauer S, Schnaiter A, Paschka P et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014; 123: 3247-3254.
    • (2014) Blood , vol.123 , pp. 3247-3254
    • Stilgenbauer, S.1    Schnaiter, A.2    Paschka, P.3
  • 12
    • 84877635463 scopus 로고    scopus 로고
    • NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome
    • Villamor N, Conde L, Martinez-Trillos A et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 2013; 27: 1100-1106.
    • (2013) Leukemia , vol.27 , pp. 1100-1106
    • Villamor, N.1    Conde, L.2    Martinez-Trillos, A.3
  • 13
    • 84874102335 scopus 로고    scopus 로고
    • Evolution and impact of subclonal mutations in chronic lymphocytic leukemia
    • Landau DA, Carter SL, Stojanov P et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013; 152: 714-726.
    • (2013) Cell , vol.152 , pp. 714-726
    • Landau, D.A.1    Carter, S.L.2    Stojanov, P.3
  • 14
    • 0033567968 scopus 로고    scopus 로고
    • Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia
    • Damle RN, Wasil T, Fais F et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
    • (1999) Blood , vol.94 , pp. 1840-1847
    • Damle, R.N.1    Wasil, T.2    Fais, F.3
  • 15
    • 0036464608 scopus 로고    scopus 로고
    • CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease
    • Hamblin TJ, Orchard JA, Ibbotson RE et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023-1029.
    • (2002) Blood , vol.99 , pp. 1023-1029
    • Hamblin, T.J.1    Orchard, J.A.2    Ibbotson, R.E.3
  • 16
    • 0344729013 scopus 로고    scopus 로고
    • Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia
    • Dighiero G, Maloum K, Desablens B et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998; 338: 1506-1514.
    • (1998) N Engl J Med , vol.338 , pp. 1506-1514
    • Dighiero, G.1    Maloum, K.2    Desablens, B.3
  • 17
    • 77951628255 scopus 로고    scopus 로고
    • Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study)
    • Robak T, Jamroziak K, Gora-Tybor J et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol 2010; 28: 1863-1869.
    • (2010) J Clin Oncol , vol.28 , pp. 1863-1869
    • Robak, T.1    Jamroziak, K.2    Gora-Tybor, J.3
  • 18
    • 33846258434 scopus 로고    scopus 로고
    • Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
    • Kay NE, Geyer SM, Call TG et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007; 109: 405-411.
    • (2007) Blood , vol.109 , pp. 405-411
    • Kay, N.E.1    Geyer, S.M.2    Call, T.G.3
  • 19
    • 84924378553 scopus 로고    scopus 로고
    • Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients ( pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study)
    • Eichhorst B, Fink AM, Busch R et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients ( pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood 2014; 124: Abstract 19.
    • (2014) Blood , vol.124
    • Eichhorst, B.1    Fink, A.M.2    Busch, R.3
  • 20
    • 84894552888 scopus 로고    scopus 로고
    • Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
    • Goede V, Fischer K, Busch R et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101-1110.
    • (2014) N Engl J Med , vol.370 , pp. 1101-1110
    • Goede, V.1    Fischer, K.2    Busch, R.3
  • 21
    • 84896480883 scopus 로고    scopus 로고
    • Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911)
    • Hillmen P, Robak T, Janssens A et al. Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911). Blood 2013; 122: Abstract 528.
    • (2013) Blood , vol.122
    • Hillmen, P.1    Robak, T.2    Janssens, A.3
  • 22
    • 84919469417 scopus 로고    scopus 로고
    • Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
    • Dreger P, Schetelig J, Andersen N et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood 2014; 124: 3841-3849.
    • (2014) Blood , vol.124 , pp. 3841-3849
    • Dreger, P.1    Schetelig, J.2    Andersen, N.3
  • 23
    • 84904252369 scopus 로고    scopus 로고
    • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
    • Byrd JC, Brown JR, O'Brien S et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213-223.
    • (2014) N Engl J Med , vol.371 , pp. 213-223
    • Byrd, J.C.1    Brown, J.R.2    O'Brien, S.3
  • 24
    • 84896692766 scopus 로고    scopus 로고
    • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia
    • Furman RR, Sharman JP, Coutre SE et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997-1007.
    • (2014) N Engl J Med , vol.370 , pp. 997-1007
    • Furman, R.R.1    Sharman, J.P.2    Coutre, S.E.3
  • 25
    • 84859472894 scopus 로고    scopus 로고
    • Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial
    • Brion A, Mahé B, Kolb B et al. Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial. Bone Marrow Transplant 2012; 47: 542-548.
    • (2012) Bone Marrow Transplant , vol.47 , pp. 542-548
    • Brion, A.1    Mahé, B.2    Kolb, B.3
  • 26
    • 84874568508 scopus 로고    scopus 로고
    • ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
    • Ghielmini M, Vitolo U, Kimby E et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 2013; 24: 561-576.
    • (2013) Ann Oncol , vol.24 , pp. 561-576
    • Ghielmini, M.1    Vitolo, U.2    Kimby, E.3
  • 27
    • 0023764718 scopus 로고
    • A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia
    • Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. N Engl J Med 1988; 319: 902-907
    • (1988) N Engl J Med , vol.319 , pp. 902-907
  • 28
    • 68449089448 scopus 로고    scopus 로고
    • Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis
    • Raanani P, Gafter-Gvili A, Paul M et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma 2009; 50: 764-772.
    • (2009) Leuk Lymphoma , vol.50 , pp. 764-772
    • Raanani, P.1    Gafter-Gvili, A.2    Paul, M.3
  • 29
    • 21144456107 scopus 로고    scopus 로고
    • Eradication of minimal residual disease in Bcell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
    • Moreton P, Kennedy B, Lucas G et al. Eradication of minimal residual disease in Bcell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971-2979.
    • (2005) J Clin Oncol , vol.23 , pp. 2971-2979
    • Moreton, P.1    Kennedy, B.2    Lucas, G.3
  • 30
    • 84860630561 scopus 로고    scopus 로고
    • Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial
    • Bottcher S, Ritgen M, Fischer K et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30: 980-988.
    • (2012) J Clin Oncol , vol.30 , pp. 980-988
    • Bottcher, S.1    Ritgen, M.2    Fischer, K.3
  • 31
    • 0031901577 scopus 로고    scopus 로고
    • Comorbidity and functional status are independent in older cancer patients
    • Extermann M, Overcash J, Lyman GH et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582-1587.
    • (1998) J Clin Oncol , vol.16 , pp. 1582-1587
    • Extermann, M.1    Overcash, J.2    Lyman, G.H.3
  • 32
    • 0035879607 scopus 로고    scopus 로고
    • Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients
    • Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis 2001; 33: 139-144.
    • (2001) Clin Infect Dis , vol.33 , pp. 139-144
    • Dykewicz, C.A.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.